Kala Pharmaceuticals Inc. - news published 212 - readings 3.207

BACK
Kala Pharmaceuticals Inc.

Kala Pharmaceuticals Inc.

Initial Registration Statement for Employee Benefit Plan (Form S-8)

As filed with the Securities and Exchange Commission on January 3, 2025 Registration No. 333-_____ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KALA BIO, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 27-0604595 (State or Other Jurisdiction of Incorporation or Orga ...

Continue reading
03.01.2025
Kala Pharmaceuticals Inc.

Kala Pharmaceuticals Inc.

Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)

Table of Contents ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ ​ FORM 10-Q ​ ​ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ​ For the quarterly period ended September 30, 2024 OR ​ ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ​ For t ...

Continue reading
12.11.2024
Kala Pharmaceuticals Inc.

Kala Pharmaceuticals Inc.

KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update Form 8 K

KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update -- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results expected in 2Q 2025 - -- Initiated five clinical trial sites for the CHASE trial in Argentina; additional sites in Latin America in process, subject to regulatory cle ...

Continue reading
12.11.2024